6,678 trials
Atopic Dermatitis
Primary: Percent Change of Trans Epidermal Water Loss (TEWL) With Use of Eucerin Lotion — 21.4 percent change
Smoking · Smoking Cessation
Primary: 7-Day Point Prevalence Abstinence From Smoking by Intervention — 43.3; 48.9; 42.3; 49.9 Percentage of participants not smoking — p=.076
Alzheimer Disease · Psychotic Disorders · Agitation
Primary: Relapse by Study Week 32 — 15; 8; 24 participants — p=0.02
Generalized Anxiety Disorder
Primary: Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 — 25.8; 24.9; 24.4; -7.7 units on a scale
Seasonal Influenza · Vaccine
Primary: Number of Subjects Who Reported At Least One Reactogenicity Sign After One Vaccination of TIV or cTIV — 1; 2; 204; 488 Subjects
Hepatitis C, Chronic · DIABETES MELLITUS Type 2
Primary: Sustained Viral Response, — 13; 11 participants
Smoking · Alcoholism
Primary: 6 Month Smoking Abstinence — 20; 12 percentage of participants abstinent
Smoking Cessation · Depression
Primary: Percentage of Participants With a Four-Week Continuous Quit Rate (CQR) — 35.9; 15.6 Percentage of participants — p=<0.0001
HIV
Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants
Osteoarthritis
Primary: Change in Knee Society Knee Score — 93.9; 93.7 scores on a scale
Diagnostic Imaging
Primary: Creatinine Clearance — 1.1; 1.9 percent change
Diabetes · Diabetes Mellitus, Type 2
Primary: Glycosylated Haemoglobin (HbA1c) — 7.34; 7.23 percentage of glycosylated haemoglobin — p=0.3406
Glioblastoma
Primary: Overall Survival (OS) — 13.17; 17.58 months
Bipolar Disorder · Weight Gain
Primary: Change in Body Mass Index (BMI) — 0.8; 1.8 kg/m2
Lumbar Spinal Stenosis
Primary: Mean Change in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). — 3.21 units on a scale — p=<0.0001